Benefits
Butyrate delivery to colon (PMC12746503 SHIME® mechanism)
PMC12746503 (Frontiers in Nutrition 2025) — IN VITRO upper GIT simulations of CoreBiome® tributyrin: 40.9% (capsule) and 48.7% (softgel) of dose hydrolyzed to butyrate in SMALL INTESTINE; 59.1% (capsule) and 51.3% (softgel) REMAINED STABLE and was AVAILABLE TO ENTER COLON. CRITICAL DISTINGUISHING ADVANTAGE: free butyrate (sodium butyrate) is rapidly absorbed in small intestine — very little reaches colon. Tributyrin enables targeted colonic butyrate delivery. Foundational pharmacokinetic mechanism evidence.
Gut microbiome + barrier function (PMC12746503 SHIME® results)
PMC12746503 SHIME® model: 3 WEEKS daily tributyrin supplementation INCREASED butyrate levels + ENHANCED ABUNDANCE of BIFIDOBACTERIUM spp. + AKKERMANSIA MUCINIPHILA. Cellular response: PROTECTIVE EFFECT on INTESTINAL BARRIER (Caco-2 cells) + IMMUNOMODULATORY PROPERTIES (THP1 co-cultures). Foundational mechanism evidence supporting clinical applications.
SCFA-butyrate UC RCT (Firoozi 2024 doi:10.1186/s12944-024-02203-z)
Firoozi D, Masoumi SJ, Mohammad-Kazem Hosseini Asl S, Labbe A, Razeghian-Jahromi I, Fararouei M et al. 2024 (Lipids Health Dis 23:216) — DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL of SCFA-BUTYRATE supplementation in patients with ACTIVE ULCERATIVE COLITIS. Outcomes: circadian-clock genes expression + sleep quality + inflammation markers. Foundational human butyrate evidence in IBD context (UC). Important emerging clinical evidence.
Anticarcinogenic actions (Heidor 2012 review)
Heidor R, Ortega JF, de Conti A, Ong TP, Moreno FS 2012 (Curr Drug Targets 13:1720-1729, doi:10.2174/138945012804545443) — review of TRIBUTYRIN ANTICARCINOGENIC ACTIONS as butyric acid prodrug. Mechanism: HDAC inhibition by butyrate + colonic delivery via tributyrin. Multiple preclinical anti-cancer evidence (colorectal cancer prevention focus). PRECLINICAL ONLY — no human cancer trials.
NCT07004257 emerging kidney stone marker trial
NCT07004257 ButOx Human Trial — open-label prospective cohort (NOT YET RECRUITING per recent status). University of British Columbia. Purpose: investigate effect of tributyrin (875 mg BID) supplementation on markers of CALCIUM OXALATE NEPHROLITHIASIS. Hypothesis: tributyrin reduces stone-formation markers via SCFA modulation. Animal data supportive. Foundational EMERGING HUMAN evidence in kidney stone disease context.
Synbiotic with Bacillus subtilis BM107 (Sung 2025 mLife mouse model)
Sung 2025 (mLife) — innovative SYNBIOTIC approach using Bacillus subtilis BM107 + tributyrin for IBD. BM107 efficiently HYDROLYZED tributyrin producing substantial butyrate levels. Mouse colitis model: REDUCED inflammation + restored gut microbiome balance. Mechanism: targeted butyrate production via microbial-substrate combination. Preclinical proof-of-concept for IBD applications.
Postbiotic concept (POSTBIOTIC vs probiotic)
Tributyrin represents POSTBIOTIC concept — directly delivers fermentation METABOLITE (butyrate) without requiring fiber substrate or live bacteria fermentation. Distinguishing pharmacological category. Mechanism advantage: bypasses fiber digestion + microbial diversity dependencies. Important framework for non-fiber-tolerant or low-microbial-diversity individuals.
Mechanism of action
Pancreatic lipase hydrolysis to colonic butyrate
Tributyrin RESISTS GASTRIC ACID + is HYDROLYZED BY PANCREATIC LIPASE in small intestine to release free butyrate. ~50-60% remains stable enough to enter colon (vs <10% for free butyrate). Distinguishing pharmacokinetic advantage.
HDAC (histone deacetylase) inhibition by butyrate
Released butyrate INHIBITS HDAC enzymes → epigenetic regulation → anti-inflammatory + anticarcinogenic effects. Mechanism for colonocyte protection + immune modulation + chemopreventive effects. Foundational butyrate mechanism.
Colonocyte energy substrate (primary fuel)
Butyrate is the PRIMARY ENERGY SOURCE for COLONOCYTES (60-70% of colon energy requirements). Mechanism for colon health, barrier function, mucin production support.
Tight junction integrity enhancement
Butyrate supports tight junction protein expression (claudins, occludin, ZO-1). Mechanism for intestinal barrier integrity — important in IBD + leaky gut contexts.
Anti-inflammatory NF-κB pathway
Butyrate suppresses NF-κB activation + reduces pro-inflammatory cytokines (TNF-α, IL-6). Mechanism for anti-inflammatory effects relevant to IBD + chronic inflammation.
Bifidobacterium + Akkermansia abundance enhancement
PMC12746503 SHIME® model: tributyrin INCREASED Bifidobacterium spp. + Akkermansia muciniphila abundance. Mechanism: butyrate cross-feeding effects on commensal microbiome.
GPR41/GPR43 SCFA receptor activation
Butyrate activates GPR41 + GPR43 (SCFA receptors) on enteroendocrine cells + immune cells. Mechanism for systemic metabolic + immune effects beyond gut-local effects.
Clinical trials
In vitro mechanism study (PMC12746503, Frontiers in Nutrition 2025).
IN VITRO upper GIT simulations + SHIME® (Simulator of the Human Intestinal Microbial Environment) model + Caco-2/THP1 co-cultures. Capsule + softgel formulations of CoreBiome® tributyrin. 3 weeks daily supplementation simulation.
40.9% (capsule) + 48.7% (softgel) hydrolyzed to butyrate in SMALL INTESTINE; 59.1% + 51.3% REMAINED STABLE TO ENTER COLON. INCREASED butyrate levels + ENHANCED Bifidobacterium spp + Akkermansia muciniphila. PROTECTIVE intestinal barrier + immunomodulatory effects. Foundational mechanism evidence — human in vivo evidence emerging.
Double-blind randomized controlled trial (Firoozi D et al. 2024, Lipids Health Dis 23:216, doi:10.1186/s12944-024-02203-z).
Patients with ACTIVE ULCERATIVE COLITIS. SCFA-butyrate supplementation vs placebo. Outcomes: circadian-clock gene expression + sleep quality + inflammation markers.
Foundational human evidence supporting butyrate supplementation in active UC context. Multi-domain effects on circadian + sleep + inflammation — broader than typical UC trial endpoints. Important emerging clinical evidence transitioning preclinical findings to human IBD applications.
Open-label prospective cohort study (NCT07004257 ButOx Human Trial). University of British Columbia. STATUS: NOT YET RECRUITING.
Patients with KIDNEY STONE DISEASE. Tributyrin 875 mg BID. Urine + stool parameters of kidney stone disease assessed.
PILOT STUDY EMERGING — investigates tributyrin influence on calcium oxalate nephrolithiasis markers. Animal data supportive. Important emerging EMERGING APPLICATION beyond IBD/cancer focus. Foundational human study transitioning preclinical kidney stone reduction findings.
About this ingredient
TRIBUTYRIN is a TRIGLYCERIDE composed of GLYCEROL + 3 BUTYRIC ACID molecules — functions as BUTYRATE PRODRUG. Distinct from sodium butyrate (free butyrate salt — rapidly absorbed, doesn't reach colon, unpleasant odor). Commercialized as COREBIOME® by Compound Solutions.
CRITICAL DISTINGUISHING ADVANTAGE: oral free butyrate is RAPIDLY ABSORBED in small intestine — very little reaches colon despite butyrate being the PRIMARY ENERGY SOURCE for COLONOCYTES (60-70% of colon energy requirements). Tributyrin RESISTS GASTRIC ACID + is HYDROLYZED BY PANCREATIC LIPASE to release butyrate ~50-60% in colon. POSTBIOTIC concept — directly delivers fermentation METABOLITE without requiring fiber substrate or live bacteria fermentation. PIVOTAL CLINICAL EVIDENCE: PMC12746503 (Frontiers in Nutrition 2025) PIVOTAL IN VITRO upper GIT simulations + SHIME® model + Caco-2/THP1 co-cultures — 40.9% (capsule) + 48.7% (softgel) hydrolyzed to butyrate in SMALL INTESTINE; 59.1% + 51.3% STABLE TO ENTER COLON. 3 weeks tributyrin INCREASED butyrate levels + ENHANCED Bifidobacterium spp + Akkermansia muciniphila + PROTECTIVE intestinal barrier + immunomodulatory effects. FIROOZI 2024 (Lipids Health Dis 23:216) DOUBLE-BLIND RCT in active UC — circadian-clock gene + sleep + inflammation outcomes. NCT07004257 ButOx Human Trial KIDNEY STONE markers EMERGING (875 mg BID, NOT YET RECRUITING). HEIDOR 2012 (Curr Drug Targets 13:1720-1729) anticarcinogenic actions review (PRECLINICAL — colorectal cancer prevention focus, no human cancer trials). SUNG 2025 (mLife) SYNBIOTIC Bacillus subtilis BM107 + tributyrin IBD mouse model (PRECLINICAL).
MECHANISMS: PANCREATIC LIPASE HYDROLYSIS to colonic butyrate (DISTINGUISHING pharmacokinetic advantage); HDAC INHIBITION by butyrate (epigenetic anti-inflammatory + anticarcinogenic); COLONOCYTE PRIMARY ENERGY SUBSTRATE (60-70% of colon energy); TIGHT JUNCTION INTEGRITY enhancement; NF-κB ANTI-INFLAMMATORY pathway; BIFIDOBACTERIUM + AKKERMANSIA abundance enhancement; GPR41/GPR43 SCFA receptor activation. EVIDENCE: 2/5 reflects: (1) PMC12746503 PIVOTAL IN VITRO mechanism study with SHIME® + Caco-2/THP1 evidence — methodologically rigorous BUT IN VITRO ONLY, (2) FIROOZI 2024 emerging human butyrate UC RCT (broader SCFA-butyrate not tributyrin-specific), (3) NCT07004257 emerging kidney stone marker trial NOT YET RECRUITING, (4) MULTIPLE preclinical animal + cell studies (anticarcinogenic, IBD synbiotic, etc.), (5) WELL-CHARACTERIZED butyrate mechanisms (HDAC, colonocyte energy, tight junction, NF-κB, GPR41/43), (6) PHARMACOKINETIC ADVANTAGE of colonic delivery distinct from free butyrate, (7) POSTBIOTIC CATEGORY — direct metabolite delivery, (8) HONEST LIMITATIONS — PRIMARILY IN VITRO + ANIMAL evidence, HUMAN CLINICAL TRIALS LIMITED, (9) industry-sponsored evidence (Compound Solutions CoreBiome®) — important context, (10) higher-evidence than typical 'butyrate supplement' due to tributyrin pharmacokinetic advantage but lower than typical probiotic due to limited human RCTs. SAFETY: Generally favorable based on food-grade glyceride origin + limited human data; long-term human safety + dose-finding trials limited. Best positioned as: (a) GUT BARRIER + COLONIC HEALTH adjunct (PMC12746503 mechanism evidence), (b) UC + IBD adjunct (Firoozi 2024 broader SCFA-butyrate evidence), (c) BIFIDOBACTERIUM + AKKERMANSIA support (microbiota cross-feeding mechanism), (d) POSTBIOTIC ALTERNATIVE for those with low fiber tolerance or low microbial diversity, (e) COREBIOME® preferred branded preparation for clinical evidence-matched formulation, (f) PREGNANCY: precautionary avoidance, (g) PANCREATIC ENZYME DEFICIENCY: reduced hydrolysis efficiency — consider digestive enzymes, (h) NOT replacement for live probiotics — distinct mechanism (postbiotic vs probiotic), (i) higher-evidence than free butyrate but lower-evidence than mainstream probiotics due to limited human RCTs. Honest framing: Tributyrin (CoreBiome®) is an INTERESTING POSTBIOTIC butyrate prodrug with pharmacokinetic advantage over free butyrate — PMC12746503 SHIME® model + Caco-2/THP1 mechanism evidence is methodologically rigorous IN VITRO support for colonic butyrate delivery + microbiota effects + barrier function + immunomodulation.
CRITICAL HONEST LIMITATION: most evidence is IN VITRO + ANIMAL — HUMAN CLINICAL TRIALS LIMITED. Firoozi 2024 broader SCFA-butyrate UC RCT supports IBD applications generically. NCT07004257 kidney stone marker trial emerging but NOT YET RECRUITING. Heidor 2012 anticarcinogenic actions are PRECLINICAL ONLY — no human cancer trials. Sung 2025 IBD synbiotic mouse model is preclinical proof-of-concept. Pharmacokinetic advantage over free butyrate (sodium butyrate) is genuinely distinguishing — colonic delivery enables effects free butyrate cannot achieve. POSTBIOTIC concept is biologically valid framework for non-fiber-tolerant or low-microbial-diversity individuals. CoreBiome® industry sponsorship warrants caveat. Reasonable gut health + colonic butyrate adjunct based on pharmacokinetic + mechanism evidence — but human clinical evidence limited compared to mainstream probiotics; emerging evidence base.